🟢 BioCryst Pharmaceuticals is trading 4.28% up on October 7, 2026 — no clear catalyst identified

BioCryst Pharmaceuticals is trading at $8.29, up 4.28%, with the reason for the October 7 gain unclear.

• The seven-member scientific advisory board was announced October 5; JPMorgan’s price-target increase was reported as an earlier action. Neither establishes a direct reason for the session’s move.
• Broader conditions were weak, including a reported biotech-sector decline, so the gain did not appear to track the available sector or market context.